Shilpa Medicare gets EIR from USFDA for Raichur API manufacturing site

20 Apr 2020 Evaluate

Shilpa Medicare has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at API manufacturing site located at Raichur, Karnataka, India during the period between February 03 and February 07 2020. The USFDA has determined that the inspection classification of this facility is No Action Indicated (NAI).

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

312.25 -11.45 (-3.54%)
23-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1756.35
Dr. Reddys Lab 1252.55
Cipla 1222.70
Zydus Lifesciences 860.55
Lupin 2297.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×